Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide with intensive behavioural therapy in overweight or obesity
NCT03611582Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2018
- Primary completion
- Mar 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide 2.4 mg with Placebo (2 arms). Primary endpoints: Percentage Change in Body Weight at 68 weeks and Participants Achieving Body Weight Reduction >= 5% at 68 weeks. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03611582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611582.